IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Receive News & Ratings for Imunon ...

For example, using this advanced technology, researchers developed an IL-12 immunotherapy called IMNN-001 that uses a DNA plasmid vector encased in a nanoparticle delivery system to deliver IL-12 ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

[212Pb]VMT01 is being tested in combination with Opdivo in a phase 1/2a trial for melanoma patients with positive MC1R imaging scans. The FDA granted fast track designation to [212Pb]VMT01 for ...

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

Alumis stock opened at $4.92 on Wednesday. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The stock has a fifty day moving average of $5.49 and a two-hundred day ...

Immunic Inc (IMUX) is expected to report $-0.23 for 4Q. Imunon Inc (IMNN) is expected to report $-0.38 for 4Q. Kirkland's Inc (KIRK) is expected to report $0.52 for 4Q. Kodiak Sciences Inc (KOD ...